Xiaopeng Sang
Bristol-Myers Squibb (Germany)(DE)Discovery Centre(CA)
Publications by Year
Research Areas
Growth Hormone and Insulin-like Growth Factors, Metabolism, Diabetes, and Cancer, PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Discovery of a 1H-Benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity(2005)134 cited
- → Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development(2009)94 cited
- → Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)(2007)40 cited
- → 2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924(2008)26 cited
- → Microwave-assisted synthesis of primary amine HX salts from halides and 7 M ammonia in methanol(2003)26 cited
- → Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors(2008)25 cited
- → SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors(2010)25 cited
- → Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3(2011)16 cited
- → 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors(2015)11 cited
- → Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation(2026)